Pharm.hamptonu.edu

Ayman M. Noreddin, PhD., RPh.
Associate Professor and Chair
Department of Pharmacy Practice
Dr. Noreddin joined the School of Pharmacy at Hampton University in August 2009 as chairperson of the Department of Pharmacy Practice. His ultimate goal is to promote the department’s academic excellence in teaching, service and scholarly activities. Dr. Noreddin has outstanding records of scientific and academic accomplishments with multiple research funding, numerous publications in highly prestigious journals and various presentations in both national and international conferences. He served as a scientific reviewer for the NIH as well as other national and international research institutions. Education
• Leadership Fellow, Academic Leadership Program, American Association of Colleges
• Fellowship, Infectious Disease Research Fellowship. American College of Clinical
• Fellowship, Pharmacokinetics/Pharmacodynamics (PK/PD) Research Fellowship,
Faculty of Medicine, University of Manitoba • Visiting Scholar (Molecular Biology and Cancer Research), School of Medicine,
• Ph.D., Pharmaceutical Sciences (Clinical Pharmacy), School of Pharmacy , University of
• M.Sc., Pharmaceutical Sciences (Biochemistry), Faculty of Pharmacy , Cairo University
• BS Pharmacy, Faculty of Pharmacy , Cairo University
Research Interests
• Pharmacoklinetic/Pharmacodynamic modeling of anti-infective and anti-cancer therapy • Clinical simulation and Monte Carlo analysis • Bacterial resistance in biofilm studies • Cancer epigenetic studies • Minority health care studies Research Focus
• Anti-infective translational research in relation to antimicrobial resistance: Our goal
is to improve patient care by maximizing clinical outcomes and preventing the development of bacterial resistance. • Anti-Cancer translational research in relation to 3D modeling and epigenetic
studies: Our goal is to optimize cancer chemotherapy and overcome/reverse the
development of resistance
Approach taken by my research program is defined by both bench investigations as well as clinical simulation studies: • In-Vitro Pharmacokinetic/Pharmacodynamic(PK/PD) modeling of anti-infective
therapy
Cutting edge in-vitro pharmacodynamic modeling techniques (for both planktonic as well
as biofilm growing cells) are utilized to mimic concentration-time profile and populations
encountered in patients. Our goal is to design strategies that optimize anti-infective
efficacy and prevent the selection of drug resistant mutants during anti-infective therapy.
• In-Vitro Pharmacokinetic/Pharamcodynamic(PK/PD) modeling of cancer
chemotherapy Advanced 3D cell culture models to evaluate administration schedules for
anti-cancer agents and epigenetic studies to optimize clinical outcome.
• Mathematical modeling and clinical simulation analysis
This translational approach involves integration of pre-clinical pharmacokinetic/pharmacodynamic data as well as early clinical pharmacokinetics/population pharmacokinetics data into mathematical modeling and Monte Carlo simulation routines. Our goal is to elucidate exposure-response relationship for target identification and optimal design of clinical trials. Recent Publications
• Ahmed GF, Elkhatib WF, and Noreddin AM. Inhibition of adhesion and invasion of
Pseudomonas aeruginosa PAO1 to A549 lung epithelial cells by some natural extracts. Journal of Infection and Public Health (Submitted). Ceftaroline pharmacodynamic activity versus community-associated and
healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant
vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-
resistant S. aureus using an in vitro model2011 Mar 23.
• Ayman M. Noreddin and Walid F. ElKhatib Antibacterial Therapy in the Elderly. In:
Frontiers in Anti-Infective Drug Discovery, Bentham Science Publishers Ltd, 2010
• Salem AH, Elkhatib WF, and Noreddin AM. Pharmacodynamic assessment of
vancomycin–rifampicin combination against methicillin resistant Staphylococcus aureus biofilm: a parametric response surface analysis. Journal of Pharmacy and Pharmacology. 63:73-79,2010. • Salem AH, Elkhatib WF, Ahmed GF, Noreddin AM.
• Noreddin AM and Elkhatib WF. Levofloxacin in the Treatment of Community Acquired
Pneumonia. Expert Review of Anti-Infective Therapy. Expert Rev Anti Infect Ther.8(5):505-14,2010. • Galal AM, Gul W, Noreddin AM, Slade D. An Update on the synthesis and antibacterial
• Noreddin AM and El-Khatib WF. Novel in vitro pharmacodynamic model simulating
ofloxacin pharmacokinetics in the treatment of Pseudomonas aeruginosa biofilm-
associated infections. Journal of Infection and Public Health.2:120-128,2009.
• El-Khatib WF and Noreddin AM. A new fluorogenic assay for monitoring and
determining planktonic and biofilm forms of Pseudomonas aeruginosa viable count in vitro. Journal of Rapid Methods and Automation in Microbiology. 17:304-314,2009. • Zhanel GG, Voth D, Nichol K, Karlowsky JA, Noreddin AM, Hoban DJ.
Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. J Antimicrob Chemother.64(2):364-9,2009. • Noreddin AM, El-Khatib WF, Aolie, J, Salem AH and Zanel GG. Pharmacodynamic
Target Attainment Potential of Azithromycin, Clarithromycin and Telithromycin in Serum and Epithelial Lining Fluid (ELF) of Community Acquired Pneumonia (CAP) Patients with Penicillin-Susceptible, Intermediate and Resistant Streptococcus pneumoniae. International Journal of Infectious Diseases.13(4):483-7.2009. • El-Khatib WF, Haynes VL and Noreddin AM. Microbiological appraisal of levofloxacin
activity against Pseudomonas aeruginosa biofilm in combination with different calcium channel blockers.Journal of Chemotherapy. 21(2): 37-45,2009. • El-Khatib WF and Noreddin AM. Novel Approach Against Central Venous Catheter
Associated Infection with Acinetobacter baumannii Biofilm.J.Med.Devices, 3(2): 027543-027543,2009. Book Chapters
• Noreddin AM. Haynes, V and El-Khatib, WF. Antimicrobial therapy in the elderly.
• Zhanel GG and Noreddin AM. Pharmacokinetics and pharmacodynamics of the new
generation quinolones. In: Recent advances in antimicrobial agents and chemotherapy. Global Reviews; 2004. • Zhanel G and Noreddin A. Pharmacokinetics and pharmacodynamics (PK/PD) of
fluoroquinolones: tools for combating bacteria and preventing resistance. In: The quinolones: an unfolding story. Birkhauser, Verlag AG, Basel, Switzerland; 2003. (Biosciences (Milestones in Drug Therapy). Honors and Awards
• Editor in Chief. InTech- Open Access Publisher, 2011 • Member of the Editorial Board of the Journal of Drug Metabolism & Toxicology, 2011 • Member of the Editorial Board of International Scholarly Research Network (ISRN) • Invited advisor to the Faculty of Pharmacy, Al-Fateh University, Tripoli, Libya, 2010. • Member of the editorial board of the “Egyptian Journal of Pharmaceutical Sciences”, • Elected advisor. Multicultural Pharmacy Students Organization, University of Minnesota, • Advisor for the Pharm.D. 2012 class, College of Pharmacy, University of Minnesota, • Teacher of the Year, College of Pharmacy, Duluth, University of Minnesota, 2007-2008 • Teacher of the Semester, College of Pharmacy, Duluth, University of Minnesota, Fall • Member of the Scientific Review Program, Division of Extramural Activities, National
Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH),
Department of Health & Human Services, 2008
• American College of Clinical Pharmacy/Aventis Pharmacotherapy Research Fellowship • Director of the continuing education and research committee - Saudi Pharmaceutical • Membership in the Rho Chi Pharmaceutical Honorary Society, CA, USA, 1986 • Graduate Students Fellowship, School of Pharmacy, University of the Pacific, 1985 • Graduate Students Representative, School of Pharmacy, University of the Pacific, 1985 • Oncology Project Grant for Pharmacy Students, the American Cancer Society, California, • Peace Fellowship to conduct graduate study in the USA, 1984 Research Support
• Co-investigator: “Innovative technologies to effectively treat multi-drug resistant and/or biofilm-embedded bacteria “, National Institute of Health (NIH)/SBIR. Grant number: 1R43GM093398-01A1, 2010-2012 ($256,000) • Co-investigator: “Collaborative Pilot Study: Evaluating the efficacy of the Drug Information Database System at Hampton University School of Pharmacy”, Hampton University Faculty Institute Grant, 2010 ($5,200) • Co-Investigator: “Relationship of MIC and AUC/MIC to vancomycin efficacy for treatment of methicillin-resistant Staphylococcus aureus pneumonia”, Whiteside Clinical Research Institute, 2008-2009 ($14,500) • Principal Investigator: “A dynamic model of bio-film infected Cystic Fibrosis lung epithelial cells”, Grant-In-AID of research, Artistry and Scholarship (Category 6, University of Minnesota 2007-2009 ($29,200) • Principal Investigator: “High throughput and in vitro modeling strategies vs. catheter biofilms in elderly patients with complicated urinary tract infections “, Society of Infectious Diseases Pharmacist, 2007-2008 ($15,000) • Principal Investigator: “Target Attainment Potential Study of Fluoroquinolones versus Resistant Strains of Streptococcuc pneumoniae” Schering Plough, 2007-2008 ($24,000) • Principal Investigator: “Pharmacodynamic Profiling of Moxifloxacin and Comparators versus Susceptible and Genetically Characterized Resistant strains of Streptococcus pneumoniae. Monte Carlo Simulation Analysis”. Schering Plough, 2006-2007 ($39,100) • Principal Investigator: “Study of the Pharmacodynamic Activity of the New Respiratory Quinolones against Ciprofloxacin Resistant Mutants of Streptococcus pneumoniae”, Grant-In-AID of Research, Artistry and Scholarship (Category I), University of Minnesota 2006-2008 ($28,000) • Principal Investigator: “Liquid Chromatography-Mass Spectroscopy Instrument”, Grant- In-Aid Program (Category II), University of Minnesota, 2005 ($38,000) • Recipient: “ Establishment of Clinical Pharmacology Research Laboratory with LC-MS instrument as the major component of Drug Metabolites, hormones and other sophisticated assays”.Shimadzu Equipment Grants for Research, Shimadzu Scientific Instruments. , 2005 ($51,000) • Principal Investigator: “Assessment of Moxifloxacin ability to eradicate and prevent development of Streptococcus pneumoniae resistance: Clinical simulation and Monte Carlo analysis”. Whiteside Institute for Clinical Research, St.Luke’s Hospital, 2005-2006 ($10.000) • Principal Investigator: “Target Attainment Analysis for Gatifloxacin 400 Daily in Immunocompetent Elderly and Immunocompromised Patients Hospitalized with Community Acquired Pneumonia”. Bristol Meyers Squibb, 2002-2003 ($12,000) • Co-Investigator: “Simulation of Levofloxacin pharmacokinetics in patients with community acquired pneumonia”. Ortho McNeil, 2001-2002 ($22,000) “Pharmacokinetic/Pharmacodynamic modeling of various Nitrofurantoin formulations versus selected urinary tract isolates. “ Procter and Gamble, 2000-2002 ($160.000) • Co-investigator: “Pharmacodynamic modeling of Macrolides/ Ketolides against macrolide-resistant S.pneumoniae ”. ABBOTT Laboratories, 2000-2001 ($50.000)

Source: http://pharm.hamptonu.edu/docs/Noreddin_Biosketch.pdf